« Back
Home /
ABT-869

ABT-869

Item no.	M1640-50mg
Manufacturer	AbMole
CASRN	796967-16-3
Amount	50mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	>98.5%
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Linifanib
Similar products	ABT-869, Linifanib
Available
Target Information	VEGFR/PDGFR
Molecular Weight	375, 41
Solubility	DMSO ≥70 mg/mL
Bioactivity information	ABT-869 (Linifanib) is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of VEGFR and PDGFR.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1640-50mg-safety-datasheet.pdf